These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29437150)

  • 21. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
    Kesarwani M; Kincaid Z; Gomaa A; Huber E; Rohrabaugh S; Siddiqui Z; Bouso MF; Latif T; Xu M; Komurov K; Mulloy JC; Cancelas JA; Grimes HL; Azam M
    Nat Med; 2017 Apr; 23(4):472-482. PubMed ID: 28319094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
    Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
    Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
    Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
    Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
    Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V; Wempe MF; Pollyea DA; Jordan CT; Serkova NJ; Graham DK; DeGregori J
    Clin Cancer Res; 2015 Mar; 21(6):1360-72. PubMed ID: 25547679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z; Peng A; Xu J; Ouyang M
    BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
    Li Y; Hu J; Song H; Wu T
    Biochem Biophys Res Commun; 2018 Nov; 505(3):858-864. PubMed ID: 30301525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
    Lin H; Rothe K; Chen M; Wu A; Babaian A; Yen R; Zeng J; Ruschmann J; Petriv OI; O'Neill K; Maetzig T; Knapp DJHF; Nakamichi N; Brinkman R; Birol I; Forrest DL; Hansen C; Humphries RK; Eaves CJ; Jiang X
    Blood; 2020 Jul; 136(5):596-609. PubMed ID: 32270193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells.
    Ozel B; Kipcak S; Biray Avci C; Gunduz C; Saydam G; Aktan C; Selvi Gunel N
    Med Oncol; 2022 Jan; 39(4):46. PubMed ID: 35092492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.
    Wang S; Xie W; Wang D; Peng Z; Zheng Y; Liu N; Dai W; Wang Y; Wang Z; Yang Y; Chen Y
    Oncotarget; 2015 May; 6(14):12128-40. PubMed ID: 25900240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
    Muselli F; Peyron JF; Mary D
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The one-two punch: combination treatment in chronic myeloid leukemia.
    Sweet KL; Hazlehurst LA; Pinilla-Ibarz J
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):667-79. PubMed ID: 23969231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
    J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.